Open access peer-reviewed Edited Volume

Cannabinoids - Recent Perspectives and Applications in Human Health

Steven P. James

Independent Researcher

Dr. James trained in Psychiatry at The New York Hospital, Cornell University, Westchester Division followed by a Psychopharmacology fellowship at Stanford University and a Research fellowship at the National Institute of Mental Health. After leaving his academic career, he pursued his interest in research and psychopharmacology within the pharmaceutical industry for over 20 years. He is a Fellow of both the American Psychiatric Association (APA) and the American Board of Sleep Medicine (ABSM).


Cannabis Delta-9 Tetrahydrocannabinoid (THC) Cannabidiol (CBD) Medical Marijuana Cannabinoid 1 Receptor (CB1) Cannabinoid 2 Receptor (CB2) Anandamide (AEA) 2-Arachidonylglycerol (2-AG) K2 Nabilone Psychedelic Spice

Register your interest in contributing to this book

Collaborate with our community and contribute your knowledge.

About the book

There is a great deal of confusion and controversy regarding Cannabinoids. The term "Cannabinoids" is applied to multiple chemical entities and their derivatives and metabolites isolated from the plant Cannabis sativa. Over 100 cannabinoids have been isolated to date and more are likely to be identified. Currently, they are classified into 11 different families and include delta-9 tetrahydrocannabinol (THC), Cannabidiol (CBD), Cannabigerol (CBG), Cannabichromene (CBC), and many others. Although used for varied purposes over human history, there is now great interest in the potential use of cannabinoids as novel medical therapeutics.

This book will discuss how these-plant derived compounds may potentially influence human health by interaction with the internal endocannabinoid system of animals. The evolution of cannabinoids in Cannabis sativa in the plant kingdom is separate from the development of the endocannabinoid system. These parallel histories led to the discovery that the biological activities of cannabinoids occurred through an accidental interaction with the endocannabinoid system.

This book explores the pressing controversy of whether cannabinoids enhance, or disrupt, critical physical activities essential to human health. From this discussion, the book will enable the reader to decide if cannabinoids present a promise of discoveries that lead to improved better therapeutics or a threat to the homeostasis critical for health.

Publishing process

Book initiated and editor appointed

Date completed: March 15th 2022

Applications to edit the book are assessed and a suitable editor is selected, at which point the process begins.

Chapter proposals submitted and reviewed

Deadline for chapter proposals: May 24th 2022

Potential authors submit chapter proposals ready for review by the academic editor and our publishing review team.

Register for the book

Approved chapters written in full and submitted

Deadline for full chapters: July 23rd 2022

Once approved by the academic editor and publishing review team, chapters are written and submitted according to pre-agreed parameters

Full chapters peer reviewed

Review results due: October 11th 2022

Full chapter manuscripts are screened for plagiarism and undergo a Main Editor Peer Review. Results are sent to authors within 30 days of submission, with suggestions for rounds of revisions.

Book compiled, published and promoted

Expected publication date: December 10th 2022

All chapters are copy-checked and typesetted before being published. IntechOpen regularly submits its books to major databases for evaluation and coverage, including the Clarivate Analytics Book Citation Index in the Web of ScienceTM Core Collection. Other discipline-specific databases are also targeted, such as Web of Science's BIOSIS Previews.

About the editor

Steven P. James

Independent Researcher

Steven James is the author of the recent book 'The Clinician's Guide to Cannabinoid Science' and advises pharmaceutical and health care providers on the clinical development of cannabinoid medications and their clinical uses. A cofounder of Clarity Telehealth, Dr James serves as Chief Medical Officer (CMO) and is a distinguished lifetime fellow of the American Board of Psychiatry and Neurology, and lifetime fellow of the American Board of Sleep Medicine. Before publishing 'The Clinician's Guide to Cannabinoid Science', Dr. James worked for over three decades in the pharmaceutical and medical device industries including Lilly, Merck-Serono and Allergan. Before starting his career in pharmaceuticals, he trained in psychiatry at the New York-Presbyterian/Weill Cornell Medical Center and research fellowship at Stanford University School of Medicine. After training he served for three years at the National Institute of Mental Health (NIMH) and as an assistant professor at the University of Pennsylvania School of Medicine.

View profile

Book chapters authored 1

Books edited 0

Introducing your Author Service Manager

Ms. Tea Jurcic

Ask a question

Book will be abstracted and indexed in